Which kidney disease can cause persistent uremic encephalopathy?

Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD)

Persistent uremic encephalopathy is caused by advanced chronic kidney disease (CKD Stages 4-5) or end-stage renal disease (ESRD), where severely reduced kidney function leads to accumulation of uremic toxins that cause neurotoxicity and brain dysfunction. 1, 2

Primary Kidney Disease Stages That Cause Uremic Encephalopathy

CKD Stage 4 and Stage 5 (GFR <30 mL/min/1.73 m²) are the kidney disease stages that cause persistent uremic encephalopathy. 3 The syndrome develops because:

• Absent or severely reduced kidney function prevents excretion of uremic toxins, leading to their systemic accumulation 3
• Uremic solutes accumulate in the brain, causing neurotoxicity, blood-brain barrier injury, neuroinflammation, oxidative stress, and brain metabolism dysfunction 2, 4
• Multiple metabolic derangements occur including acidosis, electrolyte abnormalities (hypocalcemia, hyperphosphatemia, hyperkalemia), and hormonal alterations 1, 2

Clinical Presentation of Persistent Uremic Encephalopathy

The syndrome manifests as a continuum of neurological dysfunction that worsens without treatment: 1, 5

• Cognitive impairment ranging from mild confusion to deep coma 5
• Movement disorders including asterixis, myoclonic jerks, and motor apraxia 3, 2
• Behavioral changes with personality alterations, spatial disorientation, and paranoid behavior 3
• Seizures in advanced cases 3, 2

Distinguishing From Dialysis-Related Encephalopathy

Critical distinction: While uremic encephalopathy occurs in CKD patients not yet on dialysis or inadequately dialyzed patients, there are separate aluminum-related encephalopathy syndromes in dialysis patients: 3

Dialysis Encephalopathy (Aluminum Toxicity)

• Insidious onset after 12-24 months of dialysis 3
• Progressive speech disorder (stuttering, stammering, inability to talk) 3
• Plasma aluminum levels of 150-350 µg/L 3
• Symptoms worsen shortly after dialysis 3
• Fatal within 6-12 months if untreated 3

Acute Aluminum Neurotoxicity

• Fulminant presentation with plasma aluminum 400-1,000 µg/L 3
• Occurs in CKD Stage 3-4 patients given aluminum gels plus citrate salts (which enhance aluminum absorption) 3
• Commonly fatal with agitation, confusion, myoclonic jerks, seizures, coma, and death 3

Diagnostic Approach

The diagnosis is often made retrospectively when symptoms improve after dialysis or transplantation, as there are no defining clinical, laboratory, or imaging findings. 1

Key diagnostic steps:

• Rule out alternative causes of encephalopathy (Table 4 differential includes diabetic emergencies, alcohol, drugs, infections, electrolyte disorders, intracranial bleeding) 6
• Check for precipitating factors including infection, bleeding, constipation, hyponatremia, and sepsis 6
• In dialysis patients, measure plasma aluminum levels if aluminum toxicity suspected 3
• Consider uremic encephalopathy and hepatic encephalopathy overlap in end-stage liver disease 6

Treatment Strategy

Initiate renal replacement therapy (dialysis or transplantation) as a therapeutic trial in the appropriate clinical context: 7, 1

• Indications for urgent dialysis include persistent hyperkalemia, severe metabolic acidosis, volume overload unresponsive to diuretics, and overt uremic symptoms including severe encephalopathy 7
• Cognitive impairment is a major indication for initiating renal replacement therapy 5
• Neurological symptoms that fail to improve after clearance improvement should prompt search for alternative diagnoses 1

Dialysis Considerations

• Frequent (daily) dialysis may be needed for severe cases 7
• Continuous renal replacement therapy (CRRT) is preferred for hemodynamically unstable patients 7
• Monitor for dialysis disequilibrium syndrome when initiating dialysis 8

Common Pitfall

Do not overlook metformin use in dialysis patients with diabetic nephropathy presenting with extrapyramidal symptoms and basal ganglia lesions—metformin is often inappropriately prescribed in end-stage renal disease and can cause a rapidly reversible encephalopathy when discontinued. 9